期刊文献+

抗IL-13Rα2单克隆抗体轻链和重链可变区基因的克隆及鉴定 被引量:2

下载PDF
导出
摘要 目的:在成功制备小鼠抗人IL-13Rα2高亲和力单克隆抗体(mAb)的基础上,通过分子克隆方法获得该抗体可变区基因序列。方法:从1株小鼠抗人IL-13Rα2 mAb杂交瘤细胞LX147-7中提取总RNA,以此为模板反转录获得cDNA,用针对小鼠mAb重链和轻链可变区基因序列的特异性引物分别进行PCR反应。将PCR产物连入克隆载体,经筛选阳性克隆,PCR和酶切鉴定正确后送测序,测序结果进行生物信息学分析。结果:成功克隆了抗人IL-13Rα2 mAb LX147-7重链和轻链的可变区基因。结论:获得了抗人IL-13Rα2 mAb LX147-7重链和轻链的可变区基因序列,为构建相关基因工程抗体打下了良好基础。
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2012年第9期964-967,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金面上项目(30972683 31070749)
  • 相关文献

参考文献12

  • 1Daines MO, Tabata Y, Walker BA, et al. Level of expression of IL- 13R alpha 2 impacts receptor distribution and IL-13 signaling[J]. J Immunol, 2006, 176 (12) : 7495 - 7501.
  • 2Shimamura T, Husain SR, Purl RK. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy [ J ]. Neurosurg Focus, 2006, 20(4) : Ell.
  • 3Fujisawa T, Joshi B, Nakajirna A, et al. A novel role of interleukin- 13 receptor alpha2 in pancreatic cancer invasion and metastasis J J. Cancer Re8, 2009, 69(22) : 8678 -8685.
  • 4Kunwar S, Chang S, Westphal M, et al. Phase Ill randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma [J]. Neum Oncol, 2010, 12(8) : 871 -881.
  • 5Fujisawa T, Nakashima H, Nakajima A, et al. Targeting IL- l3 Ralpha2 in human pancreatic ductal adenocarcinoma with combina- tion therapy of IL-13-PE and gemcitabine[ J]. Int J Cancer, 2011, 128(5) : 1221 - 1231.
  • 6I.ai EW, Joshi BH, Martiniova L, eta/. Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy[ J]. J Clin Endo- crinol Metab, 2009, 94(8) : 2952 -2957.
  • 7Kioi M, Kawakami M, Shimamura T, eta/. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy[J]. Cancer, 2006, 107(6): 1407-1418.
  • 8Kawakami K, Terabe M, Kioi M, et al. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL- 13Ralpha2-expressing eontralateral tumors [ J]. Clin Cancer Res, 2006, 12(15) : 4678 -4686.
  • 9Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-betal production and fibrosis[J]. Nat Med, 2006, 12(1) : 99 -106.
  • 10Shimamura T, Fujisawa T, Husain SR, et al. Interleukin 13 medi- ates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy[J]. Clin Cancer Res, 2010, 16(2) : 577 - 586.

同被引文献61

  • 1张彬彬,焦杨文,蔡卫民,陶君,刘荣华.γ干扰素治疗对日本血吸虫病肝纤维化小鼠转化生长因子β1及其受体的影响[J].中国寄生虫学与寄生虫病杂志,2004,22(6):340-343. 被引量:9
  • 2孙中文,陶然,陆艳红,石云杰,於葛华,邱玉华,张学光.5株鼠抗人CD28单克隆抗体的研制及生物学特性的研究[J].中国免疫学杂志,2005,21(6):406-410. 被引量:11
  • 3瞿秋霞,陈永井,葛彦,王勤,陈成,杨明峰,张学光.抗人CD40人-鼠嵌合抗体的构建及其表达[J].细胞与分子免疫学杂志,2006,22(2):189-192. 被引量:10
  • 4Beyersdorf N, Hanke T, KerKau T, et al. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases[ J]. Ann Rheum Dis, 2005,64 (14) : 91 -95.
  • 5Arnold K, Bordoli L, Kopp J, et al. The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling [ J ]. Bioinformatics, 2006, 22 (2) : 195 - 201.
  • 6Kiefer F, Arnold K, Kanzli M, et al. The SWISS-MODEL Repository and associated resources[J]. Nucleic Acids Res, 2009, 37 (Database issue) : D387 - D392.
  • 7Kundrotas PJ, Zhu Z, Janin J, et al. Templates are available to model nearly all complexes of structurally characterized proteins [ J ]. Proc Natl Acad Sci U S A, 2012, 109(24) : 9438 -9441.
  • 8Evans EJ, Esnouf RM, Manso-Sancho R, et al. Crystal structure of a soluble CD28-Fab complex [ J ]. Nat Immunol, 2005, 6 ( 3 ) : 271 - 279.
  • 9Saphire EO, Patten PW, Pantophlet R, et al. Crystal structure of a neutralizing human IGG against HIV-1 : a template for vaccine design [J]. Science, 2001,293(5532): 1155-1159.
  • 10McInemey TL, McLain L, Armstrong SJ, et al. A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event[J]. Virology, 1997, 233 (2) : 313 - 326.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部